SingleMetabolic / GLP-1Most referenced

Semaglutide 5mg

Synthetic GLP-1 receptor agonist studied for glycemic regulation, delayed gastric motility, and metabolic weight management pathways.

Mechanism

Selective glucagon-like peptide-1 (GLP-1) receptor agonist that stimulates glucose-dependent insulin release, downregulates glucagon secretion, and slows gastric motility.

Dosing

Standard laboratory titration starts at 0.25 mg administered once weekly.

Reconstitution

Add 2.0 mL bacteriostatic water to achieve a working concentration of 2.5 mg/mL.

Storage

Lyophilized: −20 °C; reconstituted: refrigerate 2–8 °C.

Mix & measure Semaglutide 5mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Semaglutide 5mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration2.50mg/mL

Draw volume0.100mL

On the syringe10.0units

Total doses in vial: 20.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–4 (Initiation)	0.25 mg once weekly	10 units (0.10 mL)
Weeks 5–8 (Step-up)	0.50 mg once weekly	20 units (0.20 mL)
Weeks 9–12 (Titration)	1.00 mg once weekly	40 units (0.40 mL)
Weeks 13+ (Target/Maintenance)	1.70–2.40 mg once weekly	68–96 units (0.68–0.96 mL)

Reconstitution Steps

1
Remove the lyophilized 5 mg semaglutide vial from −20 °C storage and allow it to equilibrate to room temperature for 15–20 minutes.
2
Sterilize the rubber stoppers of both the semaglutide vial and bacteriostatic water vial using fresh alcohol swabs.
3
Draw exactly 2.0 mL of bacteriostatic water into a clean reconstitution syringe.
4
Insert the needle at an angle and slowly inject the diluent down the inner glass wall of the vial to minimize shearing and frothing.
5
Gently swirl or roll the vial between the palms until the lyophilized powder is completely dissolved into a clear solution; do not shake vigorously.
6
Affix a laboratory label indicating the final concentration (2.5 mg/mL) and reconstitution date, then store the solution in refrigerated conditions at 2–8 °C.

Supplies Needed

Peptide Vial

Provides 5 mg of lyophilized semaglutide cake for laboratory reconstitution, sufficient for multiple research doses depending on the study phase.

Insulin Syringes (U-100)

Utilized for precise volumetric withdrawal and dosing, requiring 1 syringe per administration event (e.g., 4 syringes for a 4-week 0.25 mg phase).

Bacteriostatic Water

Serves as the sterile, preserved reconstituting diluent, requiring 2.0 mL per 5 mg vial to yield a 2.5 mg/mL concentration.

Alcohol Swabs

Used to maintain aseptic laboratory technique on vial septa and injection surfaces, typically requiring 2 swabs per dosing session.

Why researchers study it

Weight management

Glycemic control

Appetite suppression

Cardiovascular research

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Semaglutide is a modified peptide analogue of native human glucagon-like peptide-1 (GLP-1), synthesized to evaluate metabolic signaling pathways. Its primary structural engineering incorporates an amino acid substitution at position 8 to prevent cleavage by dipeptidyl peptidase-4 (DPP-4), alongside a C18 diacid fatty-acid chain linked via a hydrophilic spacer that enhances non-covalent binding to serum albumin. These chemical alterations dramatically extend its biological half-life compared to endogenous incretin peptides, making it a critical research tool for long-duration receptor stimulation studies. At the receptor level, semaglutide stimulates the GLP-1 receptor to potentiate glucose-dependent insulin secretion from pancreatic beta cells while concurrently repressing glucagon output from alpha cells. In addition to endocrine signaling within the pancreas, research indicates central nervous system interaction, particularly within hypothalamic and hindbrain nuclei governing appetite and satiety cascades. In experimental animal and translational human trials, this pathway triggers downstream delays in gastric motility, resulting in pronounced alterations in energy balance and nutrient absorption dynamics. Broadly investigated under multicenter clinical development programs such as SUSTAIN, PIONEER, and STEP, semaglutide serves as an established benchmark in investigations covering type 2 diabetes pathology, adiposity modulation, and cardiovascular risk factor reductions. Ongoing pre-clinical and translational inquiries continue to evaluate its multi-organ impact across hepatic steatosis, vascular endothelial biology, and chronic renal preservation.

References

1.Wilding et al., N Engl J Med, 2021 — Once-weekly semaglutide in adults with overweight or obesity (STEP 1)
2.Marso et al., N Engl J Med, 2016 — Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6)
3.Lincoff et al., N Engl J Med, 2023 — Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT)
4.Davies et al., Lancet, 2021 — Efficacy and safety of once-weekly semaglutide versus placebo in people with type 2 diabetes and overweight or obesity (STEP 2)